The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial

Adil Khaliq,Haroon Badshah,Yasar Shah,Inayat Ur Rehman,Kashif Ullah Khan,Long Chiau Ming,Maong Hui Cheng

DOI: https://doi.org/10.1097/md.0000000000040356

IF: 1.6

2024-11-13

Medicine

Abstract:The most common cause of chronic liver disease throughout the world is nonalcoholic fatty liver disease (NAFLD), which is also characterized by liver fibrosis and inflammation and leads to cirrhosis with progression to hepatic carcinoma in some cases. [ 1 ] NAFLD is a chronic disorder of dysmetabolic syndrome. [ 2 , 3 ] Most cases of NAFLD are characterized by imbalanced glucose levels, obesity, hypertension, hyperlipidemia, and hepatic expression disorders. [ 4 ] This disease affects more than half of the world's population with obesity and diabetes. [ 5 ] The conditions included low-density and high-density lipoprotein, total cholesterol, and hypertriglyceridemia. It has been reported that NAFLD is a presumed cause of chronic liver inflammation in Asian and Western countries. [ 6 ] The prevalence rate of NAFLD is 5% to 30%. However, in the world population, a global survey revealed that Pakistan and India are the countries with the most prevalent type 2 diabetes mellitus (T2DM) and obesity. [ 6 , 7 ] Furthermore, NAFLD incidence is very high among individuals with T2DM, and NAFLD incidence is expected to increase further. T2DM and NAFLD are frequently encountered in general practice. Given the complexity of their management, a multidisciplinary approach is often required, incorporating the expertise of gastroenterologists, diabetologists, and internists. This integrated care model is essential for addressing the multifaceted nature of these conditions. [ 8 ] T2DM and NAFLD are both highly prevalent in primary care, with T2DM affecting over 422 million people globally [ 9 ] and NAFLD affecting 25% to 30% of the general population. [ 9 , 10 ] The conditions are closely linked, especially through insulin resistance, with up to 70% of T2DM patients also having NAFLD. [ 10 ] This coexistence significantly increases the risk of cardiovascular disease and liver complications. [ 11 ] Primary care physicians play a critical role in the early detection and management of both conditions, which requires a multidisciplinary approach involving specialists in diabetology, gastroenterology, and internal medicine. [ 12 ] Effective management focuses on lifestyle changes, pharmacological treatments, and regular monitoring to prevent the progression of these chronic diseases. [ 13 ] Nonalcoholic steatohepatitis (NASH) is a destructive disorder of NAFLD characterized by inflammation, hepatic necrosis, and late fibrosis and may further progress to a crucial form of cirrhosis. [ 14 , 15 ] The early transience rate among NASH patients involves hepatocellular carcinoma and liver cirrhosis, along with extrahepatic manifestations, mostly cardiac disease. [ 3 , 16 , 17 ] The pathogenesis of NAFLD involves multiple factors, including an excessively imbalanced diet and fat-rich food ingestion, along with impaired insulin sensitivity and oxidative stress-induced damage. [ 18 ] However, persistent cellular stress and insulin insensitivity may lead to hepatic steatosis, which causes NAFLD and progression to NASH. [ 19 ] Recent evidence suggested that a sodium-glucose cotransporter 2 (SGLT2) inhibitor improved NAFLD in patients with T2DM. [ 20 ] Ertugliflozin is the newest SGLT2 inhibitor used in patients for the treatment of T2DM. It accelerates urinary glucose excretion, causing a decrease in blood glucose levels, osmotic urination and loss of calories. [ 20 , 21 ] Ertugliflozin improves glucose imbalance and beta cell function, and its effect on insulin sensitivity also decreases body mass. [ 22 ] A decrease in insulin insensitivity caused by canagliflozin treatment is very effective in all patients suffering from NAFLD. [ 23 , 24 ] Recently, established studies have shown that SGLT2 inhibitors considerably decrease body weight and body mass index in human trials. [ 20 </sup -Abstract Truncated-

medicine, general & internal